Fate Therapeutics Inc (FATE)

May 22, 2026

BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Raises Target Price to $2.2 - Moomoo

May 22, 2026

May 22, 2026

FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill

May 22, 2026

May 21, 2026

Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares - Investing.com UK

May 21, 2026

May 21, 2026

Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com - Investing.com Australia

May 21, 2026

May 21, 2026

Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction - Stock Titan

May 21, 2026

May 21, 2026

Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale - Stock Titan

May 21, 2026

May 21, 2026

Fate Therapeutics to present CAR T-cell data at medical conferences By Investing.com - Investing.com South Africa

May 21, 2026

May 21, 2026

Fate Therapeutics to present CAR T-cell therapy data at medical conferences - StreetInsider

May 21, 2026

May 21, 2026

Fate Therapeutics to present CAR T-cell data at medical conferences - Investing.com

May 21, 2026

May 21, 2026

Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR - Stock Titan

May 21, 2026

May 20, 2026

Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential - Investing.com India

May 20, 2026

May 20, 2026

[144] FATE THERAPEUTICS INC SEC Filing - Stock Titan

May 20, 2026

May 20, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - TradingView

May 20, 2026

May 19, 2026

Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential By Investing.com - Investing.com South Africa

May 19, 2026

May 19, 2026

Jefferies Initiates Fate Therapeutics(FATE.US) With Buy Rating, Announces Target Price $4 - Moomoo

May 19, 2026

May 14, 2026

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill

May 14, 2026

May 13, 2026

Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $2.25 - Moomoo

May 13, 2026

May 13, 2026

Fate Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 13, 2026

May 13, 2026

Fate Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Key Disclosures - Minichart

May 13, 2026

May 13, 2026

Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Canada

May 13, 2026

May 13, 2026

FT819 Remodels Lupus B Cells in Clinical Trial - CRISPR Medicine News

May 13, 2026

May 13, 2026

Fate Therapeutics Reports Q1 2026 Financial Results, Advances FT819 and FT839 CAR T-Cell Trials with Extended Cash Runway into 2028 - Minichart

May 13, 2026

May 13, 2026

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 13, 2026

May 13, 2026

Fate Therapeutics (NASDAQ: FATE) narrows Q1 2026 loss as R&D costs fall - Stock Titan

May 13, 2026

May 13, 2026

Fate Therapeutics 1Q 2026: Revenue $1.3M, EPS $(0.26) — 10-Q Summary - TradingView

May 13, 2026

May 13, 2026

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - The Manila Times

May 13, 2026

May 13, 2026

Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028 - TradingView

May 13, 2026

May 13, 2026

Fate Therapeutics: Q1 Earnings Snapshot - KTVB

May 13, 2026

May 13, 2026

Fate Therapeutics reports Q1 2026 net loss $31.2M, cash and investments $174.8M; runway into 2028 - TradingView

May 13, 2026

May 13, 2026

Fate Therapeutics (NASDAQ: FATE) trims Q1 loss, extends cash runway and advances FT819 - Stock Titan

May 13, 2026

May 13, 2026

TradingKey - TradingKey

May 13, 2026

May 12, 2026

Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026 (NASDAQ:FATE) - Seeking Alpha

May 12, 2026

May 12, 2026

FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan

May 12, 2026

May 12, 2026

Fate Therapeutics presents CAR T-cell therapy data at ASGCT - Investing.com UK

May 12, 2026

May 11, 2026

Fate Therapeutics presents CAR T-cell therapy data at ASGCT By Investing.com - Investing.com South Africa

May 11, 2026

May 11, 2026

Fate Therapeutics Showcases FT819 Clinical Activity in SLE - GlobeNewswire

May 11, 2026

May 09, 2026

Fate Therapeutics (FATE) Eps Diluted (TTM) - Zacks Investment Research

May 09, 2026

May 09, 2026

Number of shareholders of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

May 09, 2026

May 09, 2026

MSN Money - MSN

May 09, 2026

May 08, 2026

FATE Technical Analysis | Trend, Signals & Chart Patterns | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill

May 08, 2026

May 07, 2026

Fate Therapeutics Inc (FATE) Stock Price Today & Analysis - Gotrade

May 07, 2026

May 07, 2026

Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k shares - Stock Titan

May 07, 2026

May 07, 2026

Fate Therapeutics Inc (FATE) News, Articles, Events & Latest Updates - Stocktwits

May 07, 2026

May 06, 2026

Director at Fate Therapeutics (NASDAQ: FATE) exercises 25,000 stock options - Stock Titan

May 06, 2026

May 06, 2026

FATE Therapeutics (NASDAQ: FATE) director exercises options, boosts direct stake - Stock Titan

May 06, 2026

May 06, 2026

Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo

May 06, 2026

May 06, 2026

HC Wainwright Issues Positive Estimate for FATE Earnings - MarketBeat

May 06, 2026

May 06, 2026

H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo

May 06, 2026

May 05, 2026

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com - Investing.com India

May 05, 2026

May 05, 2026

Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

May 05, 2026

May 05, 2026

FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program - Investing.com

May 05, 2026

May 05, 2026

Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819 - marketscreener.com

May 05, 2026